Engineered and banked iPSCs for advanced NK- and T-cell immunotherapies Review


Authors: Cichocki, F.; van der Stegen, S. J. C.; Miller, J. S.
Review Title: Engineered and banked iPSCs for advanced NK- and T-cell immunotherapies
Abstract: The development of methods to derive induced pluripotent stem cells (iPSCs) has propelled stem cell research, and has the potential to revolutionize many areas of medicine, including cancer immunotherapy. These cells can be propagated limitlessly and can differentiate into nearly any specialized cell type. The ability to perform precise multigene engineering at the iPSC stage, generate master cell lines after clonal selection, and faithfully promote differentiation along natural killer (NK) cells and T-cell lineages is now leading to new opportunities for the administration of off-the-shelf cytotoxic lymphocytes with direct antigen targeting to treat patients with relapsed/refractory cancer. In this review, we highlight the recent progress in iPSC editing and guided differentiation in the development of NK- and T-cell products for immunotherapy. We also discuss some of the potential barriers that remain in unleashing the full potential of iPSC-derived cytotoxic effector cells in the adoptive transfer setting, and how some of these limitations may be overcome through gene editing. © 2023 The American Society of Hematology
Keywords: review; cancer recurrence; advanced cancer; cancer staging; neoplasm; neoplasms; t lymphocyte; t-lymphocytes; cell function; cancer immunotherapy; cell differentiation; cancer model; cancer therapy; cancer resistance; immunotherapy; hematopoietic cell; natural killer cell; adoptive transfer; killer cells, natural; effector cell; adoptive immunotherapy; immunotherapy, adoptive; nuclear reprogramming; induced pluripotent stem cells; natural killer t cell; cytotoxic lymphocyte; clinical trial (topic); histocompatibility; induced pluripotent stem cell; humans; human; gene editing
Journal Title: Blood
Volume: 141
Issue: 8
ISSN: 0006-4971
Publisher: American Society of Hematology  
Date Published: 2023-02-23
Start Page: 846
End Page: 855
Language: English
DOI: 10.1182/blood.2022016205
PUBMED: 36327161
PROVIDER: scopus
PMCID: PMC10023718
DOI/URL:
Notes: Review -- Source: Scopus
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors